文献速递临床试验与 GCP真实世界研究与卫生经济

常规健康相关生活质量评估联合治疗信息对非转移性乳腺癌内分泌治疗依从性的影响:随机对照试验方案

Impact of routine assessment of health-related quality of life coupled with therapeutic information on compliance with endocrine therapy in patients with non-metastatic breast cancer: protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2020-06-16

该随机对照试验计划纳入342例非转移性激素受体阳性乳腺癌患者,1:1随机分为干预组和对照组。干预组在每次就诊前使用平板电脑进行HRQoL评估并将评分提供给临床医生,同时接受治疗信息工作坊和每月提醒信;对照组接受标准护理。主要终点是12个月内分泌治疗依从性。

要点

  • 干预组在每次就诊前用平板电脑完成HRQoL评估,评分反馈给临床医生。
  • 干预组同时接受三次治疗信息工作坊(处方理解、营养、疲劳)和每月提醒信。
  • 主要终点为12个月内分泌治疗依从性,两组基线均用纸笔收集HRQoL。

核心结论

  • 该研究旨在评估系统HRQoL评估联合治疗信息是否影响非转移性乳腺癌患者12个月内分泌治疗依从性。

研究设计与样本

  • 随机对照试验,计划纳入342例非转移性激素受体阳性乳腺癌且有必要接受内分泌治疗的患者。
  • 采用最小化法1:1随机分组,按年龄、分期、内分泌治疗类型和合并症有无分层。

关键数值与推荐

  • 干预组在每次就诊前使用CHES软件进行数值化HRQoL评估,并将评分提供给临床医生。
  • 治疗信息包括三次工作坊,分别涉及理解处方、营养和疲劳,并每月向患者发送提醒信。
  • 主要终点为12个月内分泌治疗依从性,HRQoL在基线(纸笔)和12个月时评估。
  • 还将评估患者对护理的满意度和临床医生对常规HRQoL评估有用性的感知。

临床怎么用

  • 若结果阳性,该干预可能作为接受内分泌治疗患者日常临床实践的一部分。
  • 系统HRQoL评估可帮助临床医生识别患者在治疗相关症状等方面的困难。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite its proven efficacy in reducing recurrence and improving survival, adherence to endocrine therapy (ET) is suboptimal in women with breast cancer (BC). Health-related quality of life (HRQoL) in BC has been widely studied and many positive effects have been highlighted. Recently, a link between HRQoL and compliance with ET has been suggested, which would suggest a potential role for HRQoL assessment in improving compliance with ET. With the advent of digital technologies, electronic collection of HRQoL on a tablet is now possible. Thus, we hypothesize that systematic HRQoL assessment (using a tablet, prior to each consultation, with presentation of scores to clinicians) coupled with therapeutic information could have an impact on 12-month compliance with ET in patients with non-metastatic BC. METHODS: In this study, we will include 342 women with non-metastatic hormone receptor-positive BC with an indication for treatment with ET. Patients will be randomly assigned 1:1 by minimization and stratified by age, stage, type of ET prescribed, and presence of comorbidities (or not) in two arms. The intervention will consist of numerical HRQoL assessment using the CHES (Computer-based Health Evaluation System) software before each consultation (with delivery of scores to clinicians) coupled with therapeutic information. Therapeutic information will consist of three workshops related to understanding the prescription, nutrition, and fatigue. A reminder letter will be sent to patients every month. Patients in the control group will follow standard care. HRQoL will be assessed using a classic "paper-pencil" collection at baseline in both arms to ensure comparability between arms and at 12 months. The primary endpoint is 12-month compliance with ET. Patient satisfaction with care and the clinicians' perception of the usefulness of routine HRQoL assessment will also be assessed. DISCUSSION: This study will allow clinicians to identify and better understand the areas in which patients who receive ET have difficulties and thus it will assist clinicians with patient management. Systematic evaluation of HRQoL could provide an additional endpoint for measuring patients' health status and treatment-related symptoms, including ET. If the results of this study are positive, this intervention could be proposed as an integral part of daily clinical practice in patients who receive ET. TRIAL REGISTRATION: ClinicalTrials.govNCT04176809. Registered Nov. 25, 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Mamguem Kamga A, Di Martino C, Anota A, et al. Impact of routine assessment of health-related quality of life coupled with therapeutic information on compliance with endocrine therapy in patients with non-metastatic breast cancer: protocol for a randomized controlled trial. Trials. 2020. PMID: 32546198. doi:10.1186/s13063-020-04397-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。